Syncona Share News (SYNC)

Syncona annual NAV falls in tough macro conditions

(Sharecast News) - Health investor Syncona reported a fall in annual net asset value, driven by falls in its listed holdings and the partial write-down of neurological gene therapy company SwanBio, partially offset by foreign exchange tailwinds and uplifts elsewhere in its portfolio.

Syncona launches new gene therapy company with GBP96 million funding

(Alliance News) - Syncona Ltd on Monday said it launched Beacon Therapeutics Holdings Ltd, a new ophthalmic therapy company, to treat patients with retinal diseases.

Syncona launches retinal disease-focussed Beacon Therapeutics

(Sharecast News) - Healthcare company developer and investor Syncona announced the launch of Beacon Therapeutics on Monday.

TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data

(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd.

LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout

(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Syncona investee Freeline swings to first-quarter profit

Syncona Ltd - London-based investor in healthcare companies - Reports first-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline is a clinical-stage biotechnology company. Freeline swings to a pretax profit of USD1.2 million in the first quarter of 2023, from a pretax loss of USD27.0 million last year. Profit is boosted by a reduction in expenses. Research & development expenses narrow to USD11.0 million from USD20.0 million, and total operating expenses similarly decrease to USD20.1 million from USD28.1 million.

Syncona say portfolio clinical company Achilles have widened losses

(Alliance News) - Syncona Ltd on Wednesday said that its portfolio company Achilles Therapeutics PLC has made losses in the first quarter of 2023, with cash equivalents falling and expenses increasing.

IN BRIEF: Syncona leads GBP22.5 million financing in Mosaic

Syncona Ltd - healthcare company focused on a portfolio of global leaders in life science - Leads GBP22.5 million Series A financing in Mosaic Therapeutics, a Cambridge England-based oncology therapeutics company. Commits GBP16.5 million alongside investment from Cambridge Innovation Capital. Reports holding value in Mosaic is GBP7.3 million following the investment of the first tranche of the Series A commitment and, once all current commitments are invested, will have a 52.8% stake in the business. Mosaic becomes Syncona's 13th company in its current portfolio.

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Syncona said direct exposure to SVB 'de minimis'

(Sharecast News) - Life sciences investor Syncona said it had a minimal exposure to the collapsed Silicon Valley Bank.

Syncona net asset value falls on "challenging" market, dollar weakness

(Alliance News) - Syncona Ltd on Tuesday reported a decline in its third quarter net asset value, noting a depreciating US dollar against sterling and a decline in the share price of investees.

Syncona NAV falls in Q3

(Sharecast News) - Healthcare company Syncona said on Tuesday that net assets had fallen in the three months ended 31 December, principally due to the declining value of its quoted holdings and foreign exchange fluctuations.

Life Science REIT lets second floor of Rolling Stock Yard in London

(Alliance News) - Life Science REIT PLC on Wednesday said it signed an agreement to lease the second floor of its Rolling Stock Yard asset near King's Cross, London, to a life science company backed by Syncona Ltd.

Syncona investee Autolus sells more American shares

(Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced that the underwriters of its public offering of American depositary shares (ADSs), which closed on 13 December, had partially exercised their option to purchase an additional 6,927,102 ADSs.